中国药房2011，Vol.22Issue(10)：903-905,3.
硼替佐米联合VAD方案治疗初治多发性骨髓瘤的临床观察
Clinical Observation of Bortezomib Combined with VAD in the Treatment of Newly Diagnosed Multiple Myeloma
孙园园 1潘静1
作者信息
- 1. 辽宁医学院附属第一医院血液科,锦州市,121000
- 折叠
摘要
Abstract
OBJECTIVE: To investigate the efficacy and safety of bortezomib combined with VAD in treatment of newly diagnosed multiple myeloma (MM).METHODS: 15 newly diagnosed MM patients were given intravenous injection of 1.3 mg· m-2 bortezomib at 1 d, 4 d, 8 d, 11 d.Every treatment course lasted for 28 d.15 patients were additionally given VAD regimen for 2 to 8 courses.Initial efficacy was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation (EBMT).Toxic reactions were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, (NCI-CTCAE, version 3.0).RESULTS: After giving different treatment courses, 3 cases obtained complete remission, 5 caserly nearly complete remission, 5 cases partial remission, 2 cases minimal remission.Clinical response rate of 15 patients was 86.7％.The most common adverse events were gastrointestinal symptoms( 11 patients), followed by peripheral neuropathy(4 patients), fatigue (4 patients), liver injury( 1 patient) and herpes zoster (1 patient).The adverse events were relieved by routine supportive care.CONCLUSION:Bortezomib combined with VAD is accurately effective in the treatment of newly diagnosed MM and tolerable.关键词
硼替佐米/VAD方案/初治多发性骨髓瘤分类
医药卫生引用本文复制引用
孙园园,潘静..硼替佐米联合VAD方案治疗初治多发性骨髓瘤的临床观察[J].中国药房,2011,22(10):903-905,3.
